Published • loading... • Updated
Ambrose expands rare disease pipeline with €161M AM-Pharma acquisition - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ambrose expands rare disease pipeline with €161M AM-Pharma acquisition - European Biotechnology Magazine
British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
